

## Glossary for ESMO Guidelines Slide set 'Management of toxicities from immunotherapy'

Access the slide set online: <http://www.esmo.org/Guidelines/ESMO-Guidelines-Slide-Sets>

<b>Ab</b> , antibody	<b>IM</b> , intramuscular
<b>AChR</b> , acetylcholine receptor	<b>INR</b> , international normalised ratio
<b>ACTH</b> , adrenocorticotrophic hormone	<b>irAE</b> , immune-related adverse event
<b>ADL</b> , activities of daily living	<b>IV</b> , intravenous
<b>AE</b> , adverse event	<b>IVIg</b> , intravenous immunoglobulin
<b>ALT</b> , antibiotic lock therapy	<b>LFT</b> , liver function test
<b>ANA</b> , antinuclear antibody	<b>LFT</b> , liver function test
<b>ANCA</b> , anti-neutrophil cytoplasmic antibody	<b>LH</b> , luteinising hormone
<b>ARDS</b> , acute respiratory distress syndrome	<b>M/C/S</b> , microscopy, culture and susceptibility
<b>AST</b> , antimicrobial susceptibility testing	<b>M/W/F</b> , Monday Wednesday Friday
<b>ATG</b> , anti-thymocyte globulin	<b>MMF</b> , mycophenolate mofetil
<b>BAL</b> , bronchoalveolar lavage	<b>MRA</b> , magnetic resonance angiogram
<b>BSA</b> , body surface area	<b>MRI</b> , magnetic resonance imaging
<b>C</b> , <i>Candida</i>	<b>MuSK</b> , muscle-specific kinase
<b>Ca</b> , calcium	<b>Mx</b> , management
<b>CHF</b> , congestive heart failure	<b>NCS/EMG</b> , nerve conduction studies/electromyography
<b>CNS</b> , central nervous system	<b>NSAID</b> , non-steroidal anti-inflammatory drug
<b>CPG</b> , Clinical Practice Guideline	<b>NYHA</b> , New York Heart Association
<b>CRP</b> , C-reactive protein	<b>od</b> , once daily
<b>CT</b> , computed tomography	<b>OS</b> , overall survival
<b>CTCAE</b> , Common Terminology Criteria for Adverse Events	<b>PCR</b> , polymerase chain reaction
<b>CTLA-4</b> , cytotoxic T-lymphocyte antigen 4	<b>PD-1</b> , programmed cell death protein 1
<b>CVA</b> , cerebrovascular accident	<b>PD-L1</b> , programmed death ligand 1
<b>DDx</b> , differential diagnosis	<b>PJP</b> , <i>Pneumocystis jiroveci</i> pneumonia
<b>DM</b> , diabetes mellitus	<b>T3</b> , triiodothyronine
<b>DRESS</b> , drug rash with eosinophilia and systemic symptoms	<b>T4</b> , thyroxine
<b>EMG</b> , electromyography	<b>TB</b> , tuberculosis
<b>ESR</b> , erythrocyte sedimentation rate	<b>TCLO</b> , transfer factor for carbon monoxide
<b>FBC</b> , full blood count	<b>tds</b> , three times a day
<b>FSH</b> , follicle-stimulating hormone	<b>TEN</b> , toxic epidermal necrolysis
<b>FT4</b> , free thyroxine	<b>TFT</b> , thyroid function test
<b>GAD</b> , glutamic acid decarboxylase	<b>TNF<math>\alpha</math></b> , Tumor Necrosis Factor alpha
<b>GBM</b> , glomerular basement membrane	<b>TPN</b> , total parenteral nutrition
<b>GBS</b> , Guillain-Barré syndrome	<b>TPO</b> , thyroid peroxidase
<b>GI</b> , gastrointestinal	<b>TSH</b> , thyroid-stimulating hormone
<b>GN</b> , glomerulonephritis	<b>UEC</b> , urea, electrolytes, creatinine
<b>HIV</b> , human immunodeficiency virus	<b>ULN</b> , upper limit of normal
<b>HRT</b> , hormone replacement therapy	<b>UPCR</b> , urine protein to creatinine ratio
<b>HSV</b> , herpes simplex virus	<b>US</b> , ultrasound
<b>ICPi</b> , immune checkpoint inhibitor	<b>VATS</b> , video-assisted thoracoscopic surgery
<b>IGF1</b> , insulin-like growth factor 1	<b>VEGF</b> , vascular endothelial growth factor
<b>IgG</b> , immunoglobulin G	<b>VitD</b> , vitamin D
	<b>WBC</b> , white blood cell